View source for Genetically modified Poliovirus (PVS-RIPO)



{{TreatmentInfo
|drug_name=Genetically modified Poliovirus (PVS-RIPO)
|category=Oncolytic virotherapy
|book_text=In 2015, this phase I trial for recurrent glioblastoma at Duke University received a boost
in public interest when an episode of the television show 60 minutes was devoted to it.
Most exceptionally, the first two patients treated in this study were complete responders.
As of March 2015 (when the 60 minutes special aired) these two complete responders
were still alive and progression-free at 33 and 34 months from treatment. 11 of 22
patients in the trial were still alive, though six of these patients were less than 6 months
from treatment. Importantly, dose escalation of PVS-RIPO failed to improve efficacy, and
the more recent patients in the trial are being treated with a smaller dose than the trial
originally started with. Read an interview with Darrel Bigner discussing this trial here.
}}